Relapsed Myasthenia Gravis after Nivolumab Treatment

Nivolumab is a newly introduced promising therapy for treating lung cancer that restores the anti-tumor immunity by disrupting programmed cell death-1-mediated immuno-suppressive signaling. Although “new-onset” autoimmune diseases are well-known immune-related adverse events, whether or not nivoluma...

Descripción completa

Detalles Bibliográficos
Autores principales: Mitsune, Ayumi, Yanagisawa, Satoru, Fukuhara, Tatsuro, Miyauchi, Eisaku, Morita, Mami, Ono, Manabu, Tojo, Yutaka, Ichinose, Masakazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064691/
https://www.ncbi.nlm.nih.gov/pubmed/29434145
http://dx.doi.org/10.2169/internalmedicine.9153-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6064691/
https://www.ncbi.nlm.nih.gov/pubmed/29434145
http://dx.doi.org/10.2169/internalmedicine.9153-17

Ejemplares similares